Quarterly ResultApr 15, 2026, 04:22 PM
Vivos Therapeutics FY2025 Revenue Up 16% to $17.5M
AI Summary
Vivos Therapeutics reported a 16% increase in full-year 2025 revenue, reaching $17.5 million, primarily driven by sleep testing services and the acquisition of The Sleep Center of Nevada. Gross profit also grew by 17% to $10.5 million, maintaining a 60% gross margin. However, operating expenses significantly increased to $30.4 million due to investments in the new business model and SCN integration, resulting in an operating loss of $19.9 million. The company is pivoting its strategy from training dentists to acquiring sleep specialty medical providers, aiming for cash flow positive operations by year-end.
Key Highlights
- Full Year 2025 revenue increased 16% to $17.5 million.
- Gross profit rose 17% to $10.5 million, with gross margin maintained at 60%.
- Operating expenses increased to $30.4 million, leading to an operating loss of $19.9 million.
- Acquired The Sleep Center of Nevada (SCN) in June 2025, driving revenue growth.
- Shifted business strategy to focus on acquisitions of sleep specialty medical providers.